Clinical trials
Decompensated Liver Cirrhosis clinical trials
Below are recruiting decompensated liver cirrhosis clinical trials, each written for real people, not researchers. We’re tracking 56 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06576934Recruiting
Early TIPS for liver cirrhosis with ascites
This study tests whether placing a small tube (called a TIPS) early in the liver can help people with cirrhosis who have their first episode of moderate to severe belly fluid buildup. The goal is to see if this early procedure improves outcomes compared to standard care.
Freiburg im BreisgauAges 18–80 - NCT06723275Recruiting
A study on liver transplant for different liver diseases
This trial is testing a new way to see how well patients do after a liver transplant. It includes people with severe cirrhosis, other end-stage liver diseases, or liver cancer.
Ghent, BelgiumAges 18–70 - NCT06675604Recruiting
Liver transplant data collection study
This study collects data from adults listed for liver transplants due to severe liver disease or liver cancer. It aims to improve transplant care by learning from real-world patient information.
ViennaAges 18–70 - NCT07413549RecruitingPhase 1/Phase 2
Stem cell injection for hepatitis B cirrhosis
This trial tests an injection of stem cells from donated umbilical cords to see if it can help people with advanced liver scarring from hepatitis B. You may be able to join if standard treatments haven’t helped enough and you aren’t able to get a liver transplant.
WuhanAges 18–75 - NCT05224960RecruitingPhase 2
Stem cell treatment for worsening liver cirrhosis
This trial tests umbilical-cord stem cells to see if they can improve outcomes in people with decompensated (worsening) cirrhosis. You may be considered if your liver disease is moderate to severe (MELD 15–30) and you do not have certain high-risk problems right now.
Lanzhou, GansuAges 18–75 - NCT07488546Enrolling by invitationPhase 1/Phase 2
HCL001 cell therapy for advanced liver cirrhosis
This trial tests a new cell injection called HCL001 for people with decompensated cirrhosis (advanced liver scarring causing complications). The goal is to see if it's safe and helps improve liver function. It may be an option if you've tried standard treatments and meet specific health criteria.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07418008Recruiting
Thinking and memory study for people with liver cirrhosis
This study is creating a new test to measure thinking and memory problems in people with liver cirrhosis. It may help doctors find these problems earlier.
Ambāla, HaryanaAges 18–75 - NCT06871111RecruitingPhase 1
Bacteria treatment study for liver disease patients
This trial tests whether giving a mixture of helpful bacteria can improve gut health in people hospitalized with serious liver problems. It aims to see if restoring these bacteria can help with recovery.
Chicago, IllinoisAges 18 years+ - NCT06741904Enrolling by invitation
Predicting liver disease worsening without invasive tests
This study looks at new, non-invasive methods to predict when chronic liver disease might get worse. It could help you and your doctor catch problems early without needing a biopsy or other invasive procedures.
Guangzhou, GuangzhouAges 18–80 - NCT07325526RecruitingPhase 2
Testing an experimental drug for liver cirrhosis caused by MASH
This study tests an investigational medicine (BI 3802876) in people with early-stage liver cirrhosis due to MASH. The goal is to see if it is well tolerated and potentially helpful.
Chandler, ArizonaAges 18–75 - NCT06223893Recruiting
Smartphone app to improve care after cirrhosis hospitalization
This study tests how well a smartphone app helps people with cirrhosis who have been hospitalized for sudden liver problems. It aims to improve care and access to treatment after you go home.
BirminghamAges 18 years+ - NCT06396897Recruiting
Hospital at Home for Cirrhosis Recovery
This study tests whether recovering from cirrhosis at home, with a nurse visiting daily, works as well as staying in the hospital. You'll be enrolled in the Hospital at Home program and need a caregiver to help for the first two days.
Indianapolis, IndianaAges 18 years+ - NCT04873102RecruitingPhase 2
Danazol for low blood counts in some people with cirrhosis
This Phase 2 study tests danazol to improve low blood counts (low white blood cells and/or low platelets) in people with certain types of cirrhosis. It also looks at who may benefit, especially those with specific inherited blood-telomere changes.
Los Angeles, CaliforniaAges 18 years+ - NCT06525623Recruiting
Early albumin for kidney injury in cirrhosis
This study tests whether giving a common fluid (albumin) early can help protect the kidneys in people with advanced liver disease who have a sudden kidney injury. It aims to see if this simple treatment can improve recovery and prevent the need for dialysis.
Boston, MassachusettsAges 18 years+ - NCT07429864Recruiting
Bulevirtide for hepatitis D: bile acids and gut bacteria
This study looks at how Bulevirtide, a treatment for hepatitis D, affects bile acids and gut bacteria. It may help patients with chronic HDV and stable liver disease who are already on HBV therapy.
RomaAges 18 years+ - NCT07298577Enrolling by invitation
Using blood test and ultrasound to find early liver cancer in Asia
This study tests whether adding a simple blood test (GAAD score) to a routine liver ultrasound can find early-stage liver cancer sooner in people with chronic liver conditions. It aims to improve detection in Asian populations at risk.
Bangkok Noi, BangkokAges 18 years+ - NCT06121479Enrolling by invitationPhase 3
Testing oral amino acid supplements for advanced liver disease
This trial tests if taking branched-chain amino acids by mouth can help people with cirrhosis and ascites (fluid in the belly). It aims to improve nutrition and reduce complications.
Bangkok, BangkokAges 18–85 - NCT04357600Enrolling by invitationPhase 1/Phase 2
Stem cell treatment for hepatitis B–related cirrhosis
This early-stage trial tests umbilical cord “mesenchymal” stem cells in people with liver scarring (cirrhosis) that is caused by hepatitis B. It may help improve liver function and related complications, but it is mainly designed to check safety and how well the treatment works.
Jakarta, DKI JakartaAges 18–65 - NCT04767945Recruiting
Cirrhosis patient hospital registry
This study keeps a record of people who have liver cirrhosis and were admitted to the hospital after a worsening event. It may help doctors better understand what leads to hospital stays and improve future care.
Banská BystricaAges 19 years+ - NCT07268196Recruiting
How a liver transplant affects sexual function
This study looks at how a liver transplant affects a person's sex life and sexual function. It includes married men who either are waiting for a transplant or have already had one with a healthy working liver.
New Delhi, National Capital Territory of DelhiAges 18–60 - NCT06449339RecruitingPhase 4
Beta-blocker study for early-stage liver scarring
This study tests a medicine called carvedilol (a non-selective beta-blocker) to see if it can prevent complications in people with advanced chronic liver disease who are at high risk but haven't had serious problems like bleeding yet.
Hong KongAges 18 years+ - NCT04512833Recruiting
CyberKnife radiation for small liver cancer with cirrhosis
This trial tests CyberKnife stereotactic body radiation therapy—targeted high-precision radiation—for small hepatocellular carcinoma (liver cancer) in people with decompensated cirrhosis. It may help if other liver cancer treatments aren’t possible, but it has strict safety rules about tumor spread and nearby organs.
BeijingAges 30–80 - NCT06015022RecruitingPhase 2
Green tea extract to prevent liver cancer in cirrhosis
This trial tests whether a green tea extract called EGCG can prevent liver cancer in people with cirrhosis. It looks at how the extract affects liver cell changes that could lead to cancer.
Dallas, TexasAges 18 years+ - NCT07610837RecruitingPhase 2
Testing AZD2389 for fatty liver disease with scarring
This study tests whether a new drug called AZD2389 is safe and well-tolerated in adults with steatotic liver disease (fatty liver) that has progressed to advanced scarring. The trial aims to see if this drug might help slow or improve liver damage in people with this condition.
Chandler, ArizonaAges 18 years+
Hear when a new Decompensated Liver Cirrhosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for decompensated liver cirrhosis?
- Yes. Clin2 currently lists 56 recruiting decompensated liver cirrhosis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a decompensated liver cirrhosis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a decompensated liver cirrhosis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.